Transmission dynamics of the M184V drug resistance mutation in primary HIV infection

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 10, 2011, Pages 2346-2349

  Wainberg, Mark A ^a,b   Moisi, Daniela ^a   Oliveira, Maureen ^a   Toni, Thomas D'Aquin ^a,b,c   Brenner, Bluma G ^a  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c Programme PACCI CIRBA   (Côte d’Ivoire)

Author keywords

Mutational deselection; Viral fitness; Viral replicative capacity

Indexed keywords

RNA DIRECTED DNA POLYMERASE; STAVUDINE; ZIDOVUDINE;

ARTICLE; GENE MUTATION; GENETIC ANALYSIS; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; M184V MUTATION; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; REAL TIME POLYMERASE CHAIN REACTION; VIRUS REPLICATION;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 80052881523     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr291     Document Type: Article

References (10)

1. Buckton AJ, Prabhu D, Motamed C et al. Increased detection of the HIV-1 reverse transcriptase M184V mutation using mutation-specific minority assays in a UK surveillance study suggests evidence of unrecognized transmitted drug resistance. HIV Med 2011; 12: 250-4.
2. Rusconi S, De Pasquale MP, Milazzo L et al. Loss of lamivudine resistance in a zidovudine and lamivudine dual-resistant HIV-1 isolate after discontinuation of in vitro lamivudine drug pressure. Antivir Ther 1998; 3: 203-7.
3. Brenner BG, Roger M, Moisi D et al. Transmission networks of drug resistance acquired in primary/early stage HIV infection. AIDS 2008; 22: 2509-15.
4. Metzner KJ, Bonhoeffer S, Fischer M et al. Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions. J Infect Dis 2003; 188: 1433-43.
5. Saag MS, Hahn BH, Gibbons J et al. Extensive variation of human immunodeficiency virus type-1 in vivo. Nature 1988; 334: 440-4.
6. Li JZ, Paredes R, Ribaudo HJ et al. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure. JAMA 2011; 305: 1327-35.
7. Masquelier B, Bhaskaran K, Pillay D et al. Prevalence of transmitted HIV-1 drug resistance and the role of resistance algorithms: data from seroconverters in the CASCADE collaboration from 1987 to 2003. J Acquir Immune Defic Syndr 2005; 40: 505-11.
8. Johnson JA, Li JF, Wei X et al. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associated with reduced treatment efficacy. PLoS Med 2008; 5: e158.
9. Brenner BG, Routy JP, Petrella M et al. Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J Virol 2002; 76: 1753-61.
10. Toni TA, Asahchop EL, Moisi D et al. Detection of human immunodeficiency virus (HIV) type 1 M184V and K103N minority variants in patients with primary infection. Antimicrob Agents Chemother 2009; 53: 1670-2.